Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/22/2025

Management of Chronic Liver Disease

Screening and Surveillance

  • Patients with chronic liver disease require regular follow-ups to monitor for disease progression, detect complications early, screen for hepatocellular carcinoma, and adjust management strategies accordingly to reduce morbidity and mortality, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1, 2
  • Clinically significant portal hypertension significantly increases the risk of decompensation events and hepatocellular carcinoma in patients with chronic liver disease, highlighting the importance of screening 1
  • All patients with advanced fibrosis (F3) or cirrhosis require ultrasound every 6 months for hepatocellular carcinoma surveillance, as recommended by the American Association for the Study of Liver Diseases 1, 2
  • Early detection of hepatocellular carcinoma significantly improves survival outcomes in patients with chronic liver disease 1
  • Post-treatment liver stiffness measurement (LSM) <12 kPa and platelet count >150 G/L can rule out clinically significant portal hypertension in patients with chronic liver disease 1

Risk Stratification and Management

  • Patients with VCTE-LSM <8 kPa or FIB-4 <1.45 can be followed up by a general practitioner, with repeat non-invasive testing annually or every 2-3 years, and a focus on lifestyle modifications and addressing risk factors 1
  • Patients with VCTE-LSM 8-12 kPa or FIB-4 1.45-3.25 require more frequent monitoring (every 6-12 months) and assessment of comorbidities, with referral to a hepatologist if comorbidities are present 1
  • Patients with VCTE-LSM >12 kPa or FIB-4 >3.25 require follow-up by a liver disease specialist, with laboratory testing every 6 months, ultrasound for hepatocellular carcinoma screening every 6 months, and endoscopic screening for varices based on risk stratification 1, 2
  • The following risk categories and recommended actions are based on liver stiffness measurements:

    Liver Stiffness (kPa) Risk Category Recommended Action
    <8 kPa LOW RISK Repeat non-invasive testing in 2-3 years
    8-12 kPa INDETERMINATE RISK Refer to hepatologist; re-evaluate in 2-3 years
    >12 kPa HIGH RISK Refer to hepatologist for further evaluation
    >16 kPa POSSIBLE CIRRHOSIS Urgent hepatology referral

Laboratory Testing and Imaging

  • Liver function tests, including ALT, AST, GGT, ALP, and bilirubin, are recommended for patients with chronic liver disease to monitor for disease progression, as suggested by the American Gastroenterological Association and the American Association for the Study of Liver Diseases 6, 7, 2
  • Platelet count is a marker for portal hypertension and should be monitored regularly in patients with chronic liver disease 2
  • Albumin and prothrombin time are measures of synthetic function and should be monitored regularly in patients with chronic liver disease 2
  • Specific viral markers, such as HBV DNA, HDV RNA, and HCV RNA, should be monitored in patients with viral hepatitis 2
  • Ultrasound every 6 months is recommended for hepatocellular carcinoma surveillance and signs of portal hypertension in patients with chronic liver disease 1, 2
  • Elastography (FibroScan) annually is recommended to assess fibrosis progression in patients with chronic liver disease 1
  • MRI/MRCP is recommended in specific etiologies, such as primary sclerosing cholangitis (PSC) 8
  • The interpretation of liver stiffness measurements is as follows:

    Liver Stiffness (kPa) Risk of Advanced Fibrosis
    <8 Low risk
    8-12 Indeterminate risk zone
    >12 High risk
    ≥15 Highly suggestive of compensated advanced chronic liver disease
    >16 Possible cirrhosis (requires referral to hepatology)

Special Considerations

  • Even after achieving viral clearance in hepatitis C, patients with advanced fibrosis still require hepatocellular carcinoma surveillance, as recommended by the American Association for the Study of Liver Diseases 1
  • Factors such as alcohol intake, obesity, and metabolic syndrome can accelerate disease progression even after treating the primary liver disease, highlighting the importance of addressing comorbidities 1
  • Extending hepatocellular carcinoma screening beyond 6 months significantly reduces the chance of detecting early-stage, treatable tumors, as recommended by the European Association for the Study of the Liver 2
  • Lifestyle modifications, including weight loss of 7-10% of body weight, and management of metabolic comorbidities, such as diabetes, hypertension, and dyslipidemia, are recommended for patients with NAFLD/NASH, with a strength of evidence level of high 7, 9
  • Complete alcohol cessation and consideration of addiction support services are recommended for patients with alcohol-related liver disease, as stated by the National Institute on Alcohol Abuse and Alcoholism 7
  • Annual non-invasive fibrosis assessment using transient elastography (FibroScan) or serum biomarkers (FIB-4, ELF test) is recommended, as recommended by the American Gastroenterological Association 7, 10
  • Increase in LSM >1.5 kPa/year indicates disease progression, according to the European Association for the Study of the Liver 8
  • Rising liver enzymes or bilirubin, new clinical signs of portal hypertension, and development of ascites, encephalopathy, or variceal bleeding are red flags for disease progression, as stated by the American Association for the Study of Liver Diseases 11